Navigation Links
Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
Date:11/24/2008

oplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in a Phase 2 clinical trial in patients with metastatic colorectal cancer and in an ongoing Phase 2 clinical trial in patients with hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

Forward Looking Statement

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, timing and results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertaintie
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Fleur’s introduces CC ... the benefits of makeup, skin care and solar ... cream is designed with specific complexion-correcting pigments to ... complexion and a healthy glow. Far more than ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
(Date:4/29/2015)... , April 29, 2015   Doximity , ... of all US doctors as members, announced a new, ... — "Apply Using Doximity." With one click, all US ... a curriculum vitae (CV) for an open job opportunity, ... directly. Eighty seven percent of physicians are ...
(Date:4/29/2015)... NY (PRWEB) April 29, 2015 Gene therapy ... replace it with the normal gene in human cardiac cells, ... Research Center at Icahn School of Medicine at Mount Sinai. ... Nature Communications. , “Genetic mutations, the small random, changes ... in the weakening heart muscle seen in patients with heart ...
Breaking Biology Technology:Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... Va., Aug. 20 Evolvent Technologies, Inc. (Evolvent), a ... government, announced today that it was awarded a contract ... for enhancements to the Bidirectional Health Information Exchange (BHIE) ... DoD information on a shared patient population. , ...
... researchers have incorporated inorganic nanoparticles that join with ... structures that have unusual optical and mechanical properties. ... growth and assembly processes of natural materials, taking ... reduce metal ions to produce nanoparticles without harsh ...
... MOUNTAIN VIEW, Calif., Aug. 19 Los ... innovator of cavity-enhanced laser-based instrumentation for analyses of gases and liquids, ... p e Analyzer (LWIA). "Our new ... of oxygen and hydrogen in liquid water on the market today," ...
Cached Biology Technology:Evolvent Awarded Health Information Exchange Contract 2Bio-enabled, surface-mediated approach produces nanoparticle composites 2Bio-enabled, surface-mediated approach produces nanoparticle composites 3Los Gatos Research Introduces Second Generation Liquid-Water Isotope Analyzer 2
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... , From neurosurgery to bar code readers, lasers have been ... introduced in the late 1950,s. Now, with the work being ... developed a way to use lasers to study the splicing ... to sustain advanced organisms, including human life. This process of ...
... study led by a University of Florida researcher uses tracking ... some of the fish swim directly to targeted locations. ... orient at large distances, with tiger sharks swimming in direct ... areas about 30 miles away, said lead author Yannis Papastamatiou, ...
... been selected as one of seven recipients to share ... to promote preventive care and reduce health care disparities ... its Centering Pregnancy program to address perinatal health care ... bring pregnant women with similar backgrounds together for group ...
Cached Biology News:Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 2Brandeis researchers use lasers, custom microscope to show gene splicing process in real time 3New UF study shows some sharks follow 'mental map' to navigate seas 2New UF study shows some sharks follow 'mental map' to navigate seas 3Boston Medical Center to receive $245,000 grant from Attorney General Martha Coakley 2
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
...
Request Info...
normal rat IgM AF647...
Biology Products: